Nabiximols as an agonist replacement therapy during cannabis withdrawal:A randomized clinical trial

JAMA Psychiatry

Volumn 71, Issue 3, 2014, Pages 281-291

  Allsop, David J ^a,b   Copeland, Jan ^a   Lintzeris, Nicholas ^c,d   Dunlop, Adrian J ^e,f   Montebello, Mark ^c   Sadler, Craig ^e   Rivas, Gonzalo R ^c   Holland, Rohan M ^e   Muhleisen, Peter ^e   Norberg, Melissa M ^g   Booth, Jessica ^a,b   McGregor, Iain S ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^d University of Sydney   (Australia)

^e New South Wales School of Space Science   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; NABIXIMOLS;

ABORIGINE; ADULT; ALCOHOL CONSUMPTION; ANXIETY; ANXIETY SENSITIVITY INDEX; ARTICLE; AUSTRALIA; BARRATT IMPULSIVENESS SCALE; CANNABIS ADDICTION; CANNABIS USE; CLINICAL FEATURE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG USE; DSM-IV-TR; FEMALE; FOLLOW UP; HUMAN; IRRITABILITY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SHEEHAN DISABILITY SCALE; SLEEP DISORDER; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SUBSTANCE USE; SUBSTITUTION THERAPY; SUICIDAL IDEATION; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADULT; AUSTRALIA; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRONABINOL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; PSYCHOTHERAPY; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84896781775     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.3947     Document Type: Article

References (74)

1. UNODC.World Drug Report 2011. United Nations Publication, Sales No. E.11.XL.10; 2011. http://www .unodc.org/documents/data-and -analysis/WDR2011/ World-Drug-Report-2011-ebook.pdf. Accessed December 6, 2013
2. HallW, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698): 1383-1391
3. Roffman R, Stephens R. Cannabis Dependence: Its Nature, Consequences and Treatment. Cambridge, England: Cambridge University Press; 2006
4. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Treatment Episode Data Set (TEDS): 1997-2007. Rockville, MD: National Admissions to Substance Abuse Treatment Services; 2009
5. Australian Institute of Health andWelfare. Alcohol and Other Drug Treatment Services in Australia 2003-04: Report on the NationalMinimum Data Set. Canberra, Australia: AIHW; 2005
6. European Monitoring Centre for Drugs and Drug Addiction. Annual Report on the State of the Drugs Problem. Luxembourg: Publications Office of the European Union; 2012. http://www.emcdda.europa .eu/publications/annual-report/2012. Accessed December 6, 2013
7. Gorelick DA, Levin KH, CopersinoML, et al. Diagnostic criteria for cannabiswithdrawal syndrome. Drug Alcohol Depend. 2012;123(1-3):141-147
8. Verweij KJ, Agrawal A, Nat NO, et al. A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5. Psychol Med. 2013;43(8):1713-1722
9. Hasin DS, Keyes KM, Alderson D,Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry. 2008;69(9):1354-1363
10. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The CannabisWithdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119(1-2):123-129
11. Budney AJ, Hughes Jr. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19(3): 233-238
12. CopersinoML, Boyd SJ, Tashkin DP, et al. Cannabiswithdrawal among non-treatment-seeking adult cannabis users.AmJ Addict. 2006;15(1):8-14
13. Cornelius JR, Chung T, Martin C,Wood DS, Clark DB. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav. 2008;33(11):1500-1505
14. HaneyM. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep. 2005;7(5):360-366
15. Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA. Δ9- Tetrahydrocannabivarin testingmay not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend. 2010;106(1):65-68
16. Preuss UW,Watzke AB, Zimmermann J,Wong JW, Schmidt CO. Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend. 2010;106(2-3):133-141
17. Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction. 2008;103(5):787-799
18. Allsop DJ, Copeland J, Norberg MM, et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One. 2012;7(9):e44864. doi:10.1371/journal.pone.0044864
19. Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother. 2008;8(3):479-491
20. Vandrey R, HaneyM. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs. 2009;23(7):543-553
21. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011;17(14):1351-1358
22. HaneyM,Ward AS, Comer SD, Hart CL, Foltin RW, FischmanMW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155(2):171-179
23. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009;18(1):53-64
24. HaneyM, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29(1):158-170
25. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13(1):21-32
26. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol. 2009;23(1):84-93
27. HaneyM, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2008;197(1):157-168
28. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86(1):22-29
29. Vandrey R, Stitzer ML,Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128(1-2):64-70
30. HaneyM, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38(8):1557-1565
31. Karschner EL, DarwinWD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Δ9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66-75
32. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19-27.
33. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974;28(1):172-177.
34. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94. doi:10.1038 /tp.2012.15
35. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1)(suppl):82-88
36. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology (Berl). 1982;76(3):245-250
37. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3364-3378
38. Schier AR, Ribeiro NP, Silva AC, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012;34(suppl 1):S104-S110
39. Crippa JA, Hallak JE, Machado-de-Sousa JP, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38(2):162-164
40. Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10(5):675-685
41. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? a double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434-441
42. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729-1743
43. Rog DJ, Nurmikko TJ, Young CA. Oromucosal Δ9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079
44. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc). 2006;42(8):495-503
45. Schoedel KA, Chen N, Hilliard A, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011;26(3):224-236
46. FirstM, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders: Research Version, Non-Patient Edition. (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002
47. Sastre-Garriga J, Vila C, Clissold S, Montalban X. THC and CBD oromucosal spray (Sativex) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother. 2011;11(5):627-637
48. Norberg MM, Copeland J, Rivas G, Montebello M. Quitting Cannabis in 8 Days: Self-guided Manual. Sydney, Australia: National Cannabis Prevention and Information Centre, University of New South Wales; 2011
49. Norberg MM, Mackenzie J, Copeland J. Quantifying cannabis use with the timeline followback approach: a psychometric evaluation. Drug Alcohol Depend. 2012;121(3):247-252
50. Copeland J, Gilmour S, Gates P, SwiftW. The Cannabis Problems Questionnaire: factor structure, reliability, and validity. Drug Alcohol Depend. 2005;80(3):313-319
51. Lawrinson P, Copeland J, Indig D. Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: the Brief Treatment Outcome Measure (BTOM). Drug Alcohol Depend. 2005;80(1):125-133
52. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555-560
53. Martin G, Copeland J, Gates P, Gilmour S. The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend. 2006;83(1):90-93
54. SwiftW, Copeland J, HallW. Choosing a diagnostic cut-off for cannabis dependence. Addiction. 1998;93(11):1681-1692
55. Leon AC, OlfsonM, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105
56. Stephens RS,Wertz JS, Roffman RA. Self-efficacy and marijuana cessation: a construct validity analysis. J Consult Clin Psychol. 1995;63(6):1022-1031
57. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. Sydney, Australia: Psychology Foundation; 1995
58. Arnau RC, Broman-Fulks JJ, Green BA, Berman ME. The Anxiety Sensitivity Index-Revised: confirmatory factor analyses, structural invariance in Caucasian and African American samples, and score reliability and validity. Assessment. 2009;16(2):165-180
59. Deacon BJ, Abramowitz JS,Woods CM, Tolin DF. The Anxiety Sensitivity Index-Revised: psychometric properties and factor structure in two nonclinical samples. Behav Res Ther. 2003;41(12):1427-1449
60. Simons J, Gaher R. The Distress Tolerance Scale: development and validation of a self-report measure. Motiv Emot. 2005;29(2):83-102. doi:10.1007/s11031-005-7955-3
61. Patton JH, StanfordMS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51(6):768-774
62. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3-15
63. Zhang P. Multiple imputation: theory and method. Int Stat Rev. 2003;71(3):581-592. http://www.jstor.org/stable/1403830
64. BellML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient reported outcomes [published online ahead of print February 19, 2013]. Stat Methods Med Res
65. Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003;13(2):179-190
66. Rubin D. Inference and missing data. Biometrika. 1976;63(3):581-592
67. HaneyM, Bedi G, Cooper ZD, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry. 2013;73(3):242-248
68. Magee L. R. measures based onWald and likelihood ratio joint significance tests. Am Stat. 1990;44:250-253. doi:10.1080 /00031305.1990. 10475731
69. Akaike H. A new look at the statistical model identification: automatic control. IEEE Transactions on Automatic Control. 1974;19(6):716-723
70. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat. 1981;6(2):107-128. http://www.jstor.org /stable/1164588
71. Norman G. Likert scales, levels of measurement and the "laws" of statistics. Adv Health Sci Educ Theory Pract. 2010;15(5):625-632
72. SwiftW,Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One. 2013;8(7):e70052. doi:10.1371 /journal.pone.0070052
73. Levin FR, Mariani JJ, Brooks DJ, PavlicovaM, ChengW, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1-3):142-150
74. Vaillant GE. What can long-term follow-up teach us about relapse and prevention of relapse in addiction? Br J Addict. 1988;83(10):1147-1157